Literature DB >> 33283138

Emergence of Concurrent Multiple EGFR Mutations and MET Amplification in a Patient With EGFR-Amplified Advanced Gastric Cancer Treated With Cetuximab.

Yoshiaki Nakamura1,2, Akinori Sasaki1, Hiroki Yukami1, Tomoko Jogo1, Akihito Kawazoe1, Yasutoshi Kuboki1, Hiroya Taniguchi1,2, Riu Yamashita3, Takeshi Kuwata4, Miho Ozawa1, Maho Nakamura1, Takayuki Yoshino1, Kohei Shitara1.   

Abstract

Entities:  

Year:  2020        PMID： 33283138      PMCID： PMC7713584          DOI： 10.1200/PO.20.00263

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  24 in total

1.  Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Authors:  Clara Montagut; Alba Dalmases; Beatriz Bellosillo; Marta Crespo; Silvia Pairet; Mar Iglesias; Marta Salido; Manuel Gallen; Scot Marsters; Siao Ping Tsai; André Minoche; Somasekar Seshagiri; Seshagiri Somasekar; Sergi Serrano; Heinz Himmelbauer; Joaquim Bellmunt; Ana Rovira; Jeff Settleman; Francesc Bosch; Joan Albanell
Journal:  Nat Med       Date:  2012-01-22       Impact factor: 53.440

2.  Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.

Authors:  Steven B Maron; Leah M Chase; Samantha Lomnicki; Sara Kochanny; Kelly L Moore; Smita S Joshi; Stacie Landron; Julie Johnson; Lesli A Kiedrowski; Rebecca J Nagy; Richard B Lanman; Seung Tae Kim; Jeeyun Lee; Daniel V T Catenacci
Journal:  Clin Cancer Res       Date:  2019-08-19       Impact factor: 12.531

3.  Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.

Authors:  Diego Kauffmann-Guerrero; Kathrin Kahnert; Jörg Kumbrink; Zulfiya Syunyaeva; Amanda Tufman; Rudolf M Huber
Journal:  Clin Lung Cancer       Date:  2018-09-21       Impact factor: 4.785

4.  Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.

Authors:  Sabrina Arena; Beatriz Bellosillo; Giulia Siravegna; Alejandro Martínez; Israel Cañadas; Luca Lazzari; Noelia Ferruz; Mariangela Russo; Sandra Misale; Iria González; Mar Iglesias; Elena Gavilan; Giorgio Corti; Sebastijan Hobor; Giovanni Crisafulli; Marta Salido; Juan Sánchez; Alba Dalmases; Joaquim Bellmunt; Gianni De Fabritiis; Ana Rovira; Federica Di Nicolantonio; Joan Albanell; Alberto Bardelli; Clara Montagut
Journal:  Clin Cancer Res       Date:  2015-01-26       Impact factor: 12.531

5.  Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.

Authors:  Razvan Cristescu; Jeeyun Lee; Michael Nebozhyn; Kyoung-Mee Kim; Jason C Ting; Swee Seong Wong; Jiangang Liu; Yong Gang Yue; Jian Wang; Kun Yu; Xiang S Ye; In-Gu Do; Shawn Liu; Lara Gong; Jake Fu; Jason Gang Jin; Min Gew Choi; Tae Sung Sohn; Joon Ho Lee; Jae Moon Bae; Seung Tae Kim; Se Hoon Park; Insuk Sohn; Sin-Ho Jung; Patrick Tan; Ronghua Chen; James Hardwick; Won Ki Kang; Mark Ayers; Dai Hongyue; Christoph Reinhard; Andrey Loboda; Sung Kim; Amit Aggarwal
Journal:  Nat Med       Date:  2015-04-20       Impact factor: 53.440

6.  Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.

Authors:  Masanori Terashima; Koji Kitada; Atsushi Ochiai; Wataru Ichikawa; Issei Kurahashi; Shinichi Sakuramoto; Hitoshi Katai; Takeshi Sano; Hiroshi Imamura; Mitsuru Sasako
Journal:  Clin Cancer Res       Date:  2012-09-12       Impact factor: 12.531

7.  Multiple pathways of selected gene amplification during adaptive mutation.

Authors:  Elisabeth Kugelberg; Eric Kofoid; Andrew B Reams; Dan I Andersson; John R Roth
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-02       Impact factor: 11.205

8.  Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Authors:  Birgit Luber; Joëlle Deplazes; Gisela Keller; Axel Walch; Sandra Rauser; Martin Eichmann; Rupert Langer; Heinz Höfler; Susanna Hegewisch-Becker; Gunnar Folprecht; Ewald Wöll; Thomas Decker; Esther Endlicher; Sylvie Lorenzen; Falko Fend; Christian Peschel; Florian Lordick
Journal:  BMC Cancer       Date:  2011-12-07       Impact factor: 4.430

9.  A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.

Authors:  Lianhai Zhang; Jie Yang; Jie Cai; Xiaoming Song; Jianyun Deng; Xuesong Huang; Dawei Chen; Mengmeng Yang; Jean-Pierre Wery; Shuangxi Li; Aiwen Wu; Ziyu Li; Zhongwu Li; Yiqiang Liu; Yiyou Chen; Qixiang Li; Jiafu Ji
Journal:  Sci Rep       Date:  2013-10-21       Impact factor: 4.379

10.  Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers.

Authors:  Aparna R Parikh; Ignaty Leshchiner; Liudmila Elagina; Lipika Goyal; Chaya Levovitz; Giulia Siravegna; Dimitri Livitz; Kahn Rhrissorrakrai; Elizabeth E Martin; Emily E Van Seventer; Megan Hanna; Kara Slowik; Filippo Utro; Christopher J Pinto; Alicia Wong; Brian P Danysh; Ferran Fece de la Cruz; Isobel J Fetter; Brandon Nadres; Heather A Shahzade; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Bruce Giantonio; Janet E Murphy; Ryan D Nipp; Eric Roeland; David P Ryan; Colin D Weekes; Eunice L Kwak; Jason E Faris; Jennifer Y Wo; François Aguet; Ipsita Dey-Guha; Mehlika Hazar-Rethinam; Dora Dias-Santagata; David T Ting; Andrew X Zhu; Theodore S Hong; Todd R Golub; A John Iafrate; Viktor A Adalsteinsson; Alberto Bardelli; Laxmi Parida; Dejan Juric; Gad Getz; Ryan B Corcoran
Journal:  Nat Med       Date:  2019-09-09       Impact factor: 53.440
View more
  5 in total

Review 1.  Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.

Authors:  Yoshiaki Nakamura; Akihito Kawazoe; Florian Lordick; Yelena Y Janjigian; Kohei Shitara
Journal:  Nat Rev Clin Oncol       Date:  2021-03-31       Impact factor: 66.675

2.  Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.

Authors:  Steven B Maron; Stephanie Moya; Federica Morano; Matthew J Emmett; Joanne F Chou; Shalom Sabwa; Henry Walch; Bryan Peterson; Alexa B Schrock; Liangliang Zhang; Yelena Y Janjigian; Sree Chalasani; Geoffrey Y Ku; Umut Disel; Peter Enzinger; Nataliya Uboha; Shumei Kato; Takayuki Yoshino; Kohei Shitara; Yoshiaki Nakamura; Anwaar Saeed; Pashtoon M Kasi; Joseph Chao; Jeeyun Lee; Marinela Capanu; Zev Wainberg; Russell Petty; Filippo Pietrantonio; Samuel J Klempner; Daniel V T Catenacci
Journal:  J Clin Oncol       Date:  2022-03-29       Impact factor: 50.717

3.  EGFR Amplification in Metastatic Colorectal Cancer.

Authors:  Giovanni Randon; Rona Yaeger; Jaclyn F Hechtman; Paolo Manca; Giovanni Fucà; Henry Walch; Jeeyun Lee; Elena Élez; Jenny Seligmann; Benedetta Mussolin; Filippo Pagani; Marco Maria Germani; Margherita Ambrosini; Daniele Rossini; Margherita Ratti; Francesc Salvà; Susan D Richman; Henry Wood; Gouri Nanjangud; Annunziata Gloghini; Massimo Milione; Alberto Bardelli; Filippo de Braud; Federica Morano; Chiara Cremolini; Filippo Pietrantonio
Journal:  J Natl Cancer Inst       Date:  2021-11-02       Impact factor: 13.506

Review 4.  Opportunities and challenges of targeting c-Met in the treatment of digestive tumors.

Authors:  Zhengchao Zhang; Dong Li; Heng Yun; Jie Tong; Wei Liu; Keqiang Chai; Tongwei Zeng; Zhenghua Gao; Yongqiang Xie
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

Review 5.  Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond.

Authors:  Maria Alsina; Josep Tabernero; Marc Diez
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.